A Medicare payment experiment finalized at the end of September arrives with a savings forecast that has a precise dollar sign on it: $177 million. The Centers for Medicare & Medicaid Services attaches that number to the out-of-pocket costs patients are expected to avoid under its Global Benchmark for Efficient Drug Pricing model, called GLOBE. It is a projection written into a regulatory analysis rather than a tally of bills already paid, and the first reduced coinsurance charge is still months away.
What the $177 million line in the final rule counts
The figure sits in the final rule, designated CMS-5545-F, which the Federal Register published on October 2, 2026. In its response to public comments, CMS writes that “the GLOBE Model is expected to generate $177 million in total out-of-pocket savings, benefiting a substantial number of OM Part B beneficiaries.” The abbreviation is the rule’s shorthand for Original Medicare Part B, the medical-insurance side that pays for drugs given in clinics and infusion centers.
Three words in that sentence set its scope. “Expected” makes it a forecast. “Total” makes it a single sum, not an annual average. “Out-of-pocket” makes it a statement about what patients pay, which is a different ledger from what Medicare itself spends. The sentence carries no year-by-year schedule, so no per-year or per-patient figure can honestly be pulled out of it.
The longer clock in the rule is the seven-year payment period, which runs from April 1, 2027 to March 31, 2034. The coinsurance reductions themselves are shorter. CMS’s GLOBE model page gives the coinsurance reduction period as April 1, 2027 to March 31, 2032.
A separate $440 million belongs to the program, not the patient
The same rule holds a second total that is easy to confuse with the first. CMS estimates $440 million in Medicare Part B net spending savings over the seven-year payment period. That is money the program expects to keep, and it is counted separately from the $177 million that patients are expected to keep. The two figures answer different questions, and a combined total would mix patient savings with program savings.
Both numbers are CMS’s own estimates, produced inside the agency’s analysis of its own rule. No outside auditor or independent actuary stands behind either one in the documents read for this piece, which is the ordinary arrangement for a rule’s impact analysis and the reason the word “expected” matters.
Coinsurance falls from 20 percent to between 2 and 12 percent
The patient-side mechanism is coinsurance, the percentage of an approved amount that Original Medicare patients pay on a clinician-administered drug. The standard rate is 20 percent. CMS says that “using illustrative 2024 data for drugs identified in Table 4, 94 percent of illustrative GLOBE Model drugs would have a beneficiary coinsurance percentage between 2 and 12 percent—well below the standard 20 percent coinsurance.”
The word “illustrative” appears twice in that sentence, and it deserves attention. The range comes from 2024 data applied to a list of drugs, not from claims that will be paid in 2027. A coinsurance range built that way is a preview of the rate. It is not a bill, and it says nothing about which individual patient will see which percentage.
The 19-country benchmark that gives the model its name
GLOBE stands for a comparison. The model measures selected drugs against a reference basket of 19 countries: Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden, Switzerland and the United Kingdom, as listed in the full text of the final rule.
CMS Administrator Dr. Mehmet Oz framed the aim in the agency’s announcement: “we’re taking action to pilot a new approach to lower costs.” The word “pilot” is the operative one. The model is a test with a defined end date, and the $177 million is the size CMS expects that test to reach for patients.
Which drugs the estimate rests on
The savings figure applies to a narrow slice of Part B. The CMS model page describes single-source drugs and sole-source biological products in the oncology, rheumatology, immunology, ophthalmology and endocrinology therapeutic classes, and it ties eligibility to annual Original Medicare spending above $100 million on a drug.
CMS’s announcement of the final rule lists what stays out: biosimilars and the reference biologicals once a biosimilar enters the market, orphan-only drugs, plasma-derived products and certain cell and gene therapies. A forecast of out-of-pocket savings is therefore a forecast about specific products, and a patient whose treatment is on the excluded list has no reason to expect a lower percentage from it.
The patient group is also partial. The model is mandatory for selected beneficiaries in designated geographic areas, covering approximately 25 percent of Original Medicare beneficiaries, and the rule describes the savings as benefiting “a substantial number” of them. CMS does not, in the sentence read for this piece, say how many.
The dates between the rule and the first lower charge
Several dates sit between the October 2 publication and a patient’s first reduced coinsurance charge. The rule takes effect November 30, 2026. Voluntary data collection begins January 1, 2027, and the performance period starts April 1, 2027. The CMS announcement gives April 1, 2027 as the point at which beneficiary out-of-pocket reductions become visible.
Until that date, the $177 million has no patient attached to it. It is an expectation about 2027 through the model’s close, drawn from a rule that has not yet produced a single reduced bill. If the drug list, the selected areas or the manufacturer response differ from what the analysis assumed, the realized total will differ from the forecast, which is simply what separates an estimate from an outcome.
What the Federal Register supports is specific and bounded: CMS expects $177 million in total out-of-pocket savings, separately estimates $440 million in Medicare Part B net spending savings over the seven-year payment period, and says 94 percent of illustrative model drugs would carry coinsurance between 2 and 12 percent.
Part B drug bills that keep arriving while a model is still a forecast
GLOBE’s expected savings are an estimate about a group of patients and drugs that cannot yet be matched to any one household, and coinsurance on clinician-administered drugs stays at the standard rate wherever the model does not apply. The practical job left over is keeping the drug bills that exist today in order and knowing which state-run help programs for Medicare costs sit alongside them.
The Medicare Cost & Coverage Protection Kit is a 10-page kit with 51 state Medicare cost-help packs and a medication and cost tracker, so state-by-state help and a running record of drug costs can be worked through together.
Open The Medicare Cost & Coverage Protection Kit to sort out Part B drug costs state by state →
This piece was drafted with AI assistance; the figures and quotations were checked against the Federal Register final rule 2026-20281 and CMS’s GLOBE model page and announcement.
